What To Do After Nvidia Resumes Sales to China
The quantum computing and AI chip market continued its climb in the last week.Rigetti Computing (RGTI) broke out to add 40.89% last week. The full-stack quantum-classical computing supplier said that it achieved “a mid-year performance milestone of 99.5% median two-qubit gate fidelity on its modular 36-qubit system, a 2x reduction in median two-qubit gate error rate from Rigetti’s previous best results on its 84-qubit single-chip Ankaa 3 system.” In the AI chip segment, Nvidia (NVDA) rose after the White House removed a chip sale restriction to China. Insiders like CEO Huang, Kress Colette, and Seawell Brooke continued to sell shares since March. Those sales are not discouraging investors from bidding NVDA stock higher.Nvidia has two risks to consider.Valuation RisksNvidia trades at a price-to-earnings ratio of around 54 times, nearly 130% above the 23.6x times sector median. Still, Nvidia’s five-year average P/E is around 63 times. This suggests that the company’s accelerated revenue growth more than compensates for paying for the stock premium.Although unlikely, the U.S. government might renew AI-related chip restrictions. That would limit the addressable market for Nvidia and Advanced Micro Devices (AMD).Your TakeawayShareholders do not need to take profits on NVDA stock. The company has a commanding moat over the competition, which suggests that profit margins will expand.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


